| Nicholas Phillips, MD | |
|
130 Fisher Rd, Berlin, VT 05602-9516 | |
| (802) 371-4100 | |
| Not Available |
| Full Name | Nicholas Phillips |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 10 Years |
| Location | 130 Fisher Rd, Berlin, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477972370 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 042.0014166 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
News Archive
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.
A study from Columbia University reveals that patients, who have been successfully treated with buprenorphine for opioid addiction, are at a greater risk of overdose after completion of the treatment. The study was titled, "Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder", and was published in the latest issue of The American Journal of Psychiatry. This study was funded and supported by the National Institute on Drug Abuse (NIDA) and the Agency for Healthcare Research and Quality.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
That didn't take long. It's barely been two weeks since Idaho regulators said they would allow the sale of health insurance that does not meet all of the Affordable Care Act's requirements — a controversial step some experts said would likely draw legal scrutiny and, potentially, federal fines for any insurer that jumped in.
BSD Medical Corporation today announced that it entered into a securities purchase agreement with two institutional investors for the sale of 1,644,737 shares of its common stock in a registered direct offering at $1.52 per share. In addition, warrants to purchase 1,233,553 shares of common stock in the aggregate will be issued to the investors.
› Verified 4 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.
A study from Columbia University reveals that patients, who have been successfully treated with buprenorphine for opioid addiction, are at a greater risk of overdose after completion of the treatment. The study was titled, "Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder", and was published in the latest issue of The American Journal of Psychiatry. This study was funded and supported by the National Institute on Drug Abuse (NIDA) and the Agency for Healthcare Research and Quality.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
That didn't take long. It's barely been two weeks since Idaho regulators said they would allow the sale of health insurance that does not meet all of the Affordable Care Act's requirements — a controversial step some experts said would likely draw legal scrutiny and, potentially, federal fines for any insurer that jumped in.
BSD Medical Corporation today announced that it entered into a securities purchase agreement with two institutional investors for the sale of 1,644,737 shares of its common stock in a registered direct offering at $1.52 per share. In addition, warrants to purchase 1,233,553 shares of common stock in the aggregate will be issued to the investors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Phillips, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 | Nicholas Phillips, MD 130 Fisher Rd, Berlin, VT 05602-9516 Ph: (802) 371-4100 |
News Archive
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.
A study from Columbia University reveals that patients, who have been successfully treated with buprenorphine for opioid addiction, are at a greater risk of overdose after completion of the treatment. The study was titled, "Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder", and was published in the latest issue of The American Journal of Psychiatry. This study was funded and supported by the National Institute on Drug Abuse (NIDA) and the Agency for Healthcare Research and Quality.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
That didn't take long. It's barely been two weeks since Idaho regulators said they would allow the sale of health insurance that does not meet all of the Affordable Care Act's requirements — a controversial step some experts said would likely draw legal scrutiny and, potentially, federal fines for any insurer that jumped in.
BSD Medical Corporation today announced that it entered into a securities purchase agreement with two institutional investors for the sale of 1,644,737 shares of its common stock in a registered direct offering at $1.52 per share. In addition, warrants to purchase 1,233,553 shares of common stock in the aggregate will be issued to the investors.
› Verified 4 days ago
Peter M Thomashow, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 130 Fisher Rd, Central Vermont Medical Center, Berlin, VT 05602 Phone: 802-371-4316 Fax: 802-371-4579 | |
Jessica E O'neil, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 286 Hospital Loop, Berlin, VT 05602 Phone: 802-229-0591 Fax: 802-223-3667 | |
Dr. Ryosuke Kawatsuji, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Central Vermont Medical Center, Berlin, VT 05602 Phone: 802-371-4100 | |
Dr. Justin R. Knapp, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4316 Fax: 802-371-4579 | |
Kenneth Elliot Adler, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 | |
Brian Joseph Rosen, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-371-4100 |